Cell Traceability System and Stem Cell Management Standards at EHL BIO

Cell Management Standards Under New Korean Legislation

EHL BIO was the first in the Republic of Korea to be certified as a 'Human Cell Management Business' under the 'Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act'. This certification is crucial for client confidence, as it covers the systematic and transparent collection, testing, and processing of cells.

This system ensures that every cell unit used in research or care has a clear origin and is maintained under optimal controlled environments. Such standards represent a significant milestone in elevating cell therapy standards, allowing patients to fully trust the quality of cells utilized for their future regenerative health goals and quality of life.

GMP Facilities and Cultivation Technology

The heart of the traceability system lies in production precision. EHL BIO operates within GMP (Good Manufacturing Practices) facilities, holding CPC (Cell Processing Center) certifications in Korea. Our facilities are equipped with high-end technology, including Class 100 cleanrooms and high-efficiency HEPA filters for confidence at every stage.

Furthermore, we utilize specialized technology for isolating and culturing stem cells from adipose tissue and urine, yielding high cell counts while maintaining excellent cell viability. With a capacity to process 6,000 lots per year and storage in liquid nitrogen tanks at -196°C, EHL BIO’s cell management system is stable and ready for use in modern regenerative medicine.

We are the first in Korea to be approved as a Human Cell Management Business, ensuring verifiable safety standards at every step.

Quality Control and Recovery Goals

EHL BIO prioritizes high quality. Products under R&D, such as ADSTEM for atopic dermatitis or KDSTEM for chronic kidney disease, undergo intensive quality checks. Our conditioned media products are INCI-registered and tested by research institutes in Korea.

Our workflow is designed for real-time data recording, starting from autologous cell extraction—which supports immune acceptance—to cultivation by researchers. This ensures that the cells delivered back to the client are of high purity and possess tissue-regenerative potential as assessed by the EHL team.

Network and Service Accessibility

Cell management standards allow EHL BIO to provide services in Southeast Asia, including Thailand via EHL Thailand, featuring a dedicated Thai coordination team. Clients can access innovations through 6 transparent steps: from initial consultation to receiving services at the EHL Cell Center in Apgujeong and post-service follow-up.

Collaborating with leading hospitals in Korea, EHL BIO is committed to delivering traceable technology at every stage. Our goal is to enhance the quality of life for every client through effective aging-well and regenerative solutions.